Výsledky vyhledávání

Akademický článek

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Autor: Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos

Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)

Abstract With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of palbociclib plus letrozole and to id

Externí odkaz: https://doaj.org/article/78438f11a5ef4e73bef2803507ca9c9e

Zobrazit plný text záznamu

Akademický článek

Repurposing Hsp90 inhibitors as antimicrobials targeting two-component systems identifies compounds leading to loss of bacterial membrane integrity

Autor: Blanca Fernandez-Ciruelos, Marco Albanese, Anmol Adhav, Vitalii Solomin, Arabela Ritchie-Martinez, Femke Taverne, Nadya Velikova, Aigars Jirgensons, Alberto Marina, Paul W. Finn, Jerry M. Wells

Publikováno v: Microbiology Spectrum, Vol 12, Iss 8 (2024)

ABSTRACT The discovery of antimicrobials with novel mechanisms of action is crucial to tackle the foreseen global health crisis due to antimicrobial resistance. Bacterial two-component signaling systems (TCSs) are attractive targets for the discovery

Externí odkaz: https://doaj.org/article/eb742db707cc4fc0822bc7e3971afb89

Zobrazit plný text záznamu

Akademický článek

'Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper'

Autor: Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Gennari, Antonio Llombart, Miguel Martìn, Francesca Poggio, Aleix Prat, Fabio Puglisi, Cristina Saura

Publikováno v: Breast, Vol 76, Iss , Pp 103742- (2024)

Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clini

Externí odkaz: https://doaj.org/article/3fd5c1f752464c7f896a88384ff626ee

Zobrazit plný text záznamu

Akademický článek

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)

Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can

Externí odkaz: https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9

Zobrazit plný text záznamu